ArticleScientific reports2025
The role of serum uric acid in frailty among individuals with reduced renal function: a cross-sectional study base on CHARLS.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential associations of febuxostat and allopurinol with incident and worsening frailty risk in nephrology patients.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Frailty is a common geriatric syndrome associated with adverse health outcomes, particularly in individuals with chronic kidney disease (CKD). However, the relationship between Serum uric acid (SUA) and frailty in individuals with reduced renal function remains unclear. This cross-sectional study utilized data from the 2015 wave of the China Health and Retirement Longitudinal Study. Participants with self-reported CKD or an estimated glomerular filtration rate < 60 mL/min/1.73 m² were included (N = 1,809). SUA levels were measured and categorized into tertiles (< 4.70 mg/dL, 4.70-6.03 mg/dL, and ≥ 6.03 mg/dL). Frailty status was assessed using a validated frailty index based on 30 health-related variables. Ordinal logistic regression and restricted cubic spline analysis were used to examine the association between SUA and frailty, adjusting for demographic, clinical, and lifestyle factors. Higher SUA levels were significantly associated with frailty. In multivariable models, participants in the highest SUA tertile had increased odds of frailty compared to the lowest tertile (odd ratio [OR] = 1.354, 95% confidence interval [95% CI]: 1.028-1.783, P = 0.031). Restricted cubic spline analysis indicated a linear relationship between SUA and frailty index (P for overall = 0.037). Subgroup analysis showed a stronger association in participants aged < 65 years (highest vs. lowest tertile: OR = 1.872, 95% CI: 1.185-2.966, P = 0.007), while no significant association was observed in those aged ≥ 65 years (highest vs. lowest tertile: OR = 1.029, 95% CI: 0.719-1.473, P = 0.877). Elevated SUA levels are independently associated with frailty in individuals with reduced renal function, particularly among younger participants. These findings suggest that SUA may serve as a potential biomarker and therapeutic target for frailty prevention in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.